Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2012-09-27 Earnings Release
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming Completes Ruconest® US Pivotal Phase III Study
Earnings Release Classification · 95% confidence The document is a press release dated September 27, 2012, announcing that Pharming Group NV has completed the clinical phase of its US pivotal Phase III study for RUCONEST®. It details the completion of patient enrollment, the next steps (database finalization and analysis), and the potential milestone payment. This type of announcement, focusing on clinical trial progress and upcoming results, is characteristic of an Earnings Release (ER) or a general press release regarding operational milestones. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, the most appropriate classification is Earnings Release (ER), as these often accompany or precede formal financial reporting periods with operational updates. Given the content is a specific operational update rather than a general regulatory filing fallback (RNS), ER is the best fit for a significant operational milestone announcement. Q3 2012
2012-09-27 English
Pharming concludes second call of €10 million equity working capital facility
Capital/Financing Update Classification · 98% confidence The document is a press release from Pharming Group NV announcing the conclusion of the second call under an Equity Working Capital facility, detailing the cash proceeds raised (€1,121,000) and the remaining available financing (€7,676,000). This content directly relates to fundraising, financing activities, and changes in capital structure (issuance of shares for cash). This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV).
2012-09-26 English
Pharming updates on ongoing call of second tranche of €10 million equity working capital facility
Share Issue/Capital Change Classification · 99% confidence The document is an announcement titled "PHARMING UPDATES ON ONGOING CALL OF SECOND TRANCHE OF €10 MILLION EQUITY WORKING CAPITAL FACILITY". It details an increase in the number of shares called under an equity facility, resulting in an increase in outstanding shares. This activity directly relates to the company's capital structure and fundraising efforts. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP), which covers fundraising and capital structure changes. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV).
2012-09-21 English
Pharming updates on ongoing call of second tranche of €10 million equity working capital facility
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Pharming Group NV dated September 18, 2012, announcing an update regarding the ongoing call of the second tranche of a €10 million equity working capital facility. It details the increase in shares called by investors and the resulting change in the total number of outstanding shares. This announcement pertains directly to the company's financing activities and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Given its specific focus on equity facility utilization, CAP is the most appropriate classification.
2012-09-18 English
Pharming updates on ongoing call of second tranche of €10 million equity working capital facility
Capital/Financing Update Classification · 95% confidence The document is a press release dated September 7, 2012, announcing an update regarding the ongoing call of an equity working capital facility (issuance of shares) and providing an update on the RUCONEST® Phase III clinical study. This content relates to financing activities (equity facility) and general corporate/product updates. It is not a formal regulatory filing like a 10-K, a quarterly report (IR), or a specific shareholder vote result (DVA). Since it details a capital/financing activity (equity issuance/working capital facility update), the most appropriate classification is Capital/Financing Update (CAP). It is too detailed to be a simple Regulatory Filing (RNS) or Report Publication Announcement (RPA), as it contains substantive operational and financial news, not just an announcement that a report is available.
2012-09-07 English
Pharming draws second tranche under €10 million equity working capital facility and provides update on pivotal Phase III Study
Capital/Financing Update Classification · 95% confidence The document is a press release dated September 5, 2012, announcing two key events: 1) Pharming drawing the second tranche under an equity working capital facility (a financing/capital activity), and 2) an update on the pivotal Phase III study for RUCONEST®. The primary focus is on the capital raise (issuance of shares) and the clinical trial progress, which directly impacts financing and future revenue potential. This content is characteristic of an announcement detailing capital structure changes and operational milestones, rather than a full regulatory report (10-K, IR) or a formal earnings release (ER). Since it explicitly details the issuance of shares under a facility, the 'Capital/Financing Update' (CAP) category is the most appropriate fit, as it covers fundraising and capital structure changes. It is not a general regulatory filing (RNS) because it fits a more specific category.
2012-09-05 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.